Immervision Brings Human-Like Vision Capabilities to Halodi Robotics
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, is proud to announce it was chosen by Halodi Robotics to provide their next generation vision system for their humanoid service robot platform, capable of handling both human and computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005594/en/
(Graphic: Business Wire)
Robots are capable of performing a wide variety of tasks that are difficult or dangerous for humans to perform. To intelligently and accurately perform these tasks, they require mobility and the aptitude to explore, understand and function within various environments. For a robot to work autonomously, or problem-solve with human assistance, it requires sensor data to understand the human world and the ability to process the data and respond in a timely manner. The difficulty is that for certain applications, a robot needs to combine both human and machine vision capabilities. While performing independent tasks, machine vision suffices, but when functioning in partnership with a human operator, human vision capabilities are needed, hence, the need for a next generation vision system.
“Robots have incredible potential to expand human capabilities and performance in the real world,” says Nicholas Nadeau, CTO of Halodi Robotics. “Immervision is able to help our EVE service robots create even greater value, by allowing human operators, via a virtual reality (VR) headset, to respond with human intuition capabilities to the anomalies that may arise as robots interact with their dynamic environment.”
Immervision’s next-gen vision system enables machines with both visual systems, for multiple sensors and wiring. Robots can now navigate within hospitals or dangerous workplaces, and the vision system can be customized to the environment and specific tasks. The vision system will enable Halodi Robotics robots to better perceive their environment, collect better quality vision data for AI/ML pipelines, as well as providing an immersive VR experience to the operator of the robots.
“Halodi Robotics approached us when searching for a fast, responsive, and immersive visual system capable of delivering wide-angle visual data simultaneously to both machine and humans,” explains Patrice Roulet Fontani, VP of Technology at Immervision. “Increased responsive speed starts with a high-quality wide-angle lens and with our patented technology and AI algorithms, we are the natural choice to optimize the performance and situational awareness across Halodi Robotics entire vision pipeline.”
Immervision has spent over 20 years adding vision to machines. The company’s vision solutions are deployed into several markets, such as automotive, drones and consumer devices, to ensure whether a robot is picking up an object or performing a specific task, they have optimized hand-eye co-ordination. Immervision’s dewarping algorithm enhances its dual next-gen vision solution, ensuring correct proportions are maintained for the entire image and real-time video for both human and machine vision.
Halodi Robotics already has multiple enterprise customer pilot programs underway in Europe and the U.S. for security, retail and logistics applications, with broader deployment planned for later this year.
With over 20 years of innovation, Immervision creates solutions that see beyond human vision. Its Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. The company invents, customises, and licenses wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. For more information: www.immervision.com.
About Halodi Robotics
Halodi Robotics builds service robots to extend growing workforces in security, retail, logistics, and healthcare. Our roboticists design and develop affordable humanoid robots with the skill to operate in unstructured environments where people and machines must work safely together. Operating in near silence with human strength, our robots enable independent automation for everyday tasks. Halodi Robotics bases our global teams at our Norway headquarters with satellite offices in Canada, Italy, and the U.S. For more information about our mission and career opportunities, go to www.halodi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Paige McEachren, Director Marketing & Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit
Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release
Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n
PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release
PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw
Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release
Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p